Introduction
Despite the application of aggressive therapies, the prognosis for suerers of ovarian cancer has improved very little in recent years. Overall, ®ve year survival remains at approximately 40% and the disease comprises the ®fth most common cause of cancer death in women and the most frequent cause of death from gynaecological malignancies in the western world (Shelling et al., 1995) . The main contributor to this poor prognosis is the fact that most ovarian tumours have spread beyond their original ovarian site at the time of diagnosis. In order for advances to be made in prognosis, a better understanding of the genetic events which initiate ovarian tumorigenesis is needed so that new strategies for early detection and treatment can be devised.
Studies of a number of epithelial malignancies, particularly colon carcinoma have established that tumorigenesis is characterized by an accumulation of chromosomal deletions corresponding to the inactivation of tumour suppressor genes (TSG) (Fearon and Vogelstein, 1990) . Analysis of mainly advanced stage ovarian cancers has also demonstrated the presence of numerous chromosomal deletions suggesting the involvement of many TSG in ovarian tumorigenesis (Gallion et al., 1992; Cliby et al., 1993; Osbourne and Leech, 1994) . Attempts at determining which of these genetic events are involved in the initiation of ovarian tumorigenesis have proved to be problematic since few early stage tumours have been available for study. Consequently, even fundamental questions concerning the aetiology of ovarian carcinomas, such as whether it arises de novo or via intermediate benign and/or borderline lesions remain unanswered.
Recent technical advances in the analysis of paran embedded archival tumour tissues have made it possible to investigate the genetic alterations occurring in early ovarian tumours. Coupled with this, the application of microdissection procedures has facilitated the analysis of biopsies containing only small areas of tumour. In this study, we have applied these techniques to the analysis of loss of heterozygosity (LOH) on chromosomes 6, 7, 9, 11 and 17 in 40 early stage ovarian carcinomas and seven borderline ovarian carcinomas obtained from both fresh and paranembedded archival tumour specimens.
Results
LOH analysis was performed using 17 polymorphic microsatellite markers on six chromosome arms thought to harbour TSG relevant to the development of ovarian or other epithelial cancers. LOH data derived from the analysis of early malignant tumours, together with the histological details are summarized in Table 1 . Thirtytwo early stage tumours (80%) exhibited LOH with at least one marker and all chromosome arms studied exhibited LOH in at least some tumours. The highest frequencies of loss were detected on chromosome arms 7p, 7q, 9p and 11q with LOH of any marker on these arms being detected in 31%, 50%, 42% and 34% of cases respectively. LOH was observed on 17p at the site of the TP53 gene in 27% of early malignant tumours examined, with two tumours also harbouring a mutation in this gene (tumour 135, 12 bp deletion; tumour 43, GTC to GAC). LOH on 6q was detected in only four of 34 informative tumours (12%). All major histological subtypes analysed exhibited LOH. LOH was signi®cantly more common on 11q in endometrioid tumours (57%) compared to mucinous tumours (10%, P50.05) and 9p LOH was signi®cantly more frequent in mucinous tumours (64%) compared to serous tumours (14%, P50.05). No signi®cant dierences could be detected between LOH frequencies in early stage malignant and borderline tumours with respect to histology.
Analysis of borderline tumours (Table 2 ) revealed a pattern of LOH similar to that observed in the early malignant specimens with frequent LOH detected on chromosome arms 7p (43%), 7q (71%), 9p (43%) and 11q (57%). However no LOH was observed on chromosome 6q or at the TP53 locus. Recent studies have suggested the presence of multiple TSGs on 7q in ovarian and other epithelial cancers centred around 7q31. Our data con®rms that LOH at 7q21-31 is frequent and consistent with other reports there appears to be at least 2 critical regions. One is indicated by tumour 219 which harbours an interstitial region of LOH¯anked by D7S491 and D7S522. A second region lies distal to D7S522 as indicated by tumours 28 and 37 which retained heterozygosity at D7S522 but demonstrated LOH with the closely linked marker D7S633. Re®nement of the candidate region is complicated by the fact that some tumours harbour interstitial deletions which overlap both these regions.
Discussion
Previous studies of early stage ovarian tumours have identi®ed regions of LOH, but the signi®cance of these ®ndings has been reduced by the small numbers of samples examined. Through the utilization of microdissected archival samples in addition to fresh tissue, we have overcome this limitation which has traditionally impeded genetic studies of early stage ovarian tumours.
We have demonstrated that LOH on 7p, 7q, 9p and 11q is common among both early stage and borderline ovarian tumours. These regions have also been reported to undergo LOH in a large proportion of late stage ovarian cancers (Chenevix-Trench et al., 1994a; Zenklussen et al., 1995; Campbell et al., 1995; Davis et al., 1996; Devlin et al., 1996) consistent with a common developmental pathway for borderline, early and late stage ovarian carcinomas. Furthermore, we recently reported frequent LOH in benign ovarian tumours (Table 3) on chromosome arms 7p (26%), and 9p (26%) (Roy et al., 1997) suggesting that inactivation of TSGs on these chromosomes may be among the earliest events in ovarian tumorigenesis. LOH on chromosome arms 7q, 11q and 17p is rare in benign tumours compared with borderline and early malignant tumours and inactivation of TSGs on these chromosomes may be involved in the transition to borderline and malignant disease.
LOH on 7q has been reported in a variety of tumours and particularly in early prostate cancers (Latil et al., 1995) , early breast tumours (Champeme et al., 1995) and uterine leiomyomas (Ishwad et al., 1995) . The particularly high frequency of LOH detected in borderline and early ovarian cancers suggests that it is also an important early event in ovarian tumorigenesis. Analysis of the frequency and distribution of LOH observed in our ovarian tumours with partial losses suggest that there are at least two critical regions on 7q. One is in the vicinity of D7S658 at 7q22.2 and another distal to D7S522 at 7q31. This is in agreement with several other studies of ovarian carcinomas (Kerr et al., 1996; Koike et al., 1997; Edelson et al., 1997) . A candidate TSG on 7q (Lane et al., 1996; Li et al., 1996) is the gene for plasminogen activator inhibitor (PAI-1) which has been reported to show a rearrangement in an Abbreviations: Het, retention of constitutional heterozygosity; loh, loss of constitutional heterozygosity; blank space, not informative due to constitutional homozygosity or not done. Benign data from Roy et al. (1997) ovarian adenocarcinomas. In the current study, LOH at the PAI-1 locus (7q22.1) was detected at a lower frequency than¯anking markers, suggesting that it may not be the target of the LOH. In addition PAI-1 mutations were not detected in any of 22 ovarian carcinomas analysed by Turkmen et al. (1997) . More detailed analysis will be required to determine the number and precise location of the TSG(s) in this region.
Our observation that LOH on chromosome 6q is relatively uncommon in early ovarian cancer contrasts with the frequent LOH observed by others in advanced ovarian tumours Foulkes et al., 1993; Osbourne and Leech, 1994) and suggests that this chromosome harbours TSG relevant to tumour progression rather than initiation. However this contradicts the ®ndings of Tibletti et al. (1996) who in a cytogenetic study suggest that abnormalities of the telomeric region of 6q (6q27) may be amongst the earliest lesions to occur during ovarian cancer development. This discrepancy may be due to the fact that our tumours were predominantly mucinous and endometrioid sub-type while those analysed by Tibletti et al. were serous and may indicate that terminal 6q LOH may be a speci®c event for serous ovarian tumours. This is consistent with other studies of advanced ovarian cancers which have found histological sub-type speci®c LOH events on chromosome 6q (Saito et al., 1992; Orphanos et al., 1995) .
LOH on chromosome 17p has been reported in approximately 60 ± 80% of advanced ovarian cancers. Our ®nding of LOH on 17p in only 27% of early ovarian cancers suggests that in general this occurs as a late event during ovarian tumorigenesis. Similarly, TP53 mutations were detected in only two cases (5%) compared with about 50% in advanced ovarian cancers. While most studies have reported similar low frequencies of 17p LOH and TP53 mutation in early stage ovarian tumours, Skomedal et al. (1997) has reported p53 over expression and/or TP53 genetic mutations in a remarkable 50% of 347 stage I ovarian carcinomas. At least part of this high detection rate may be due to the more sensitive immunohistochemical and DNA mutation detection techniques used. Resolution of this has important implications as benign or potentially preneoplastic ovarian lesions which have been shown to harbour TP53 mutations have often been dismissed as atypical' lesions based on the belief that TP53 mutation occurs only as a late event in ovarian tumorigenesis. In particular, Zheng et al. (1995) reported TP53 mutations in histologically benign cysts contiguous to ovarian carcinomas but not in any of 16 solitary cystadenomas and concluded that such cysts were not typical cystadenomas but carried a genetic predisposition to carcinogenesis not present in`ordinary' cystadenomas. We would argue that such data demonstrates simply that benign cystadenomas can give rise to malignant ovarian tumours which opens up the possibility that all malignant ovarian tumours arise through benign, and borderline precursors. Perhaps the only exceptional feature of benign lesions found contiguous with carcinomas is that they have not been obliterated by the advancing carcinoma. In this context it may be that precursors which harbour TP53 mutations are more aggressive and are less often outgrown by the carcinoma.
In conclusion, this study has demonstrated frequent LOH on chromosomes 7p, 7q, 9p and 11q in early stage and borderline ovarian tumours consistent with common developmental pathways. The LOH reported in our previous study of benign ovarian tumours is consistent with this and suggests that these are not separate diseases but represent various developmental stages of the same disease. To date there have been very few studies of benign and borderline tumours synchronous with carcinoma but in each study common genetic alterations have been detected consistent with a progression model for ovarian tumorigenesis (Zheng et al., 1993 (Zheng et al., , 1995 Werness et al., 1997) . More extensive molecular genetic analysis of benign and borderline tumours synchronous with carcinoma should permit resolution of the etiology of ovarian tumours.
Materials and methods

Tumour specimens
Forty early stage malignant and seven borderline fresh and paran-embedded epithelial ovarian tumours were obtained from hospitals throughout the Wessex region and from the pathology archives at the Southampton General Hospital. Tumour histology was con®rmed by a gynaecological pathologist (AH). When available, DNA was extracted from fresh tumour tissue using standard DNA extraction protocols described previously (MuÈ llenbach et al., 1989) . Matching peripheral blood samples were used as a source of normal DNA for comparison with the fresh tissue samples. Normal and tumour tissue-derived DNA was also obtained from archival paran-embedded specimens using the microdissection/DNA extraction protocol described below.
Microdissection and DNA extraction
Three sequential ®ve micron sections were cut from the paran embedded tumour blocks, mounted onto poly-Llysine coated slides and dewaxed in xylene and ethanol washes. One section from each block was then stained with haematoxylin and eosin using standard techniques and the desired regions of normal and tumour tissue identi®ed within the section. Using this slide as a guide, the areas corresponding to normal and tumour tissue were carefully scraped from the unstained sections with a 25 gauge needle. The DNA content of the collected material was then extracted using the Qiagen tissue extraction kit (Qiagen, Dorking, UK) following the manufacturers instructions. Puri®ed DNA was eluted into 75 ml of nuclease free water pre-warmed to 708C and stored at 48C. As illustrated in Figure 1 , the microdissection procedure employed in this study permitted tumour tissue to be eciently harvested with very little cross contamination from surrounding normal tissue. The DNA recovered by this procedure ampli®ed eciently with no evidence of non-speci®c ampli®cation of the alleles in the DNA recovered from adjacent normal tissue (Figure 2 ). Tumours consisting of clonal sub-populations of cells were identi®ed when observation of complete LOH with one marker was accompanied by the observation of partial allele loss with another, i.e. the data for primers D9S171 and D7S494 respectively in Figure 2 .
Microsatellite analysis
Forty early stage and seven borderline ovarian tumour specimens were analysed for LOH on chromosome arms 6q, 7p, 7q, 9p, 11q and 17p (TP53 gene) using microsatellite PCR analysis. PCR primer sequences are shown in Table 4 . PCR was carried out with 10 ± 200 ng of fresh tumour DNA or 1 ml of the archival DNA solution, which was found to be sucient for eective ampli®cation, in a reaction volume of 20 ml containing 1 mCi of [a-32 P]dCTP. Interference from contaminating DNA was monitored using controls in which DNA specimens were replaced by an equal volume of water. The standard PCR ampli®cation programme was as follows: one cycle of 958C for 5 min, 40 cycles of 958C for 1 min, primer annealing for 1 min and 728C for 1 min followed by one cycle of 728C for 5 min. To reduce mispriming, a hot start procedure was applied. The PCR ampli®ed products were separated on non-denaturing 5 ± 8% polyacrylamide gels, dried under vacuum and subjected to autoradiography. Assessment of LOH was determined by comparing the intensities of the alleles obtained from the normal and tumour DNA. Statistical evaluation of LOH frequencies was performed using Chisquared analysis and Fisher's exact test.
SSCP analysis and sequencing of TP53
PCR ampli®cation of exons 5 ± 8 of TP53 was carried out using the primers and conditions described by Milner et al. (1993) . SSCP analysis of the samples was performed as previously described (Campbell et al., 1994) . PCR products were sequenced using a dideoxy termination protocol (Foulkes et al., 1995) . The primer sequences are shown in the 5' to 3' orientation.
